{
    "Clinical Trial ID": "NCT00191152",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Gemcitabine Plus Docetaxel",
        "  gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous, days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous, day 1 every 21 days.",
        "  Treatment continues until progression of disease at which time crossover treatment begins.",
        "INTERVENTION 2: ",
        "  Docetaxel Plus Capecitabine",
        "  docetaxel 75 mg/m2, intravenous, day 1 every 21 days plus capecitabine 1000 mg/m2, by mouth twice a day, days 1-14 every 21 days. Treatment continues until progression of disease, at which time crossover treatment begins."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologic or cytologic confirmation of breast cancer with locally advanced and/or metastatic disease",
        "  Patients may have received prior neo-adjuvant or adjuvant taxane regimen as long as it has been greater than or equal to 6 months since completion of the regimen",
        "  Patients may have had 0-1, but no more than one prior course of chemotherapy for metastatic disease",
        "  Patients must have either measurable or non-measurable (evaluable) disease",
        "  Prior radiation therapy allowed of less than 25% of the bone marrow",
        "Exclusion Criteria:",
        "  Second primary malignancy (except in situ carcinoma of the cervix or adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated at least 5 years previously with no evidence of recurrence)",
        "  Parenchymal or leptomeningeal brain metastases",
        "  Peripheral neuropathy greater than or equal to grade 2",
        "  Prior treatment with gemcitabine and capecitabine will not be allowed. Prior treatment with a taxane in the metastatic setting will not be allowed. Prior taxane therapy in the neo-adjuvant or adjuvant setting is allowed if completion of therapy greater than or equal to 6 months prior to enrollment.",
        "  Active cardiac disease not controlled by therapy and/or myocardial infarction within the preceding 6 months.",
        "  Concomitant Herceptin is not allowed"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Time to Disease Progression (Initial Treatment)",
        "  Time to disease progression (TTDP) at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression or the date of death due to disease under study, whichever came first. TTDP censored at earliest of: 1) date of death not due to disease; or 2) date of last contact for participants alive without disease progression; or 3) start date of other anti-tumor therapy; or 4) first dose date of crossover treatment.",
        "  Time frame: Randomization date to the earliest date of first documented disease progression date or the date of death if the participant died due to study disease (up to 82 months)",
        "Results 1: ",
        "  Arm/Group Title: Gemcitabine Plus Docetaxel",
        "  Arm/Group Description: gemcitabine 1000 milligrams per meter squared (mg/m2) intravenous, days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenous, day 1 every 21 days.",
        "  Treatment continues until progression of disease at which time crossover treatment begins.",
        "  Overall Number of Participants Analyzed: 239",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  9.28        (7.73 to 10.79)",
        "Results 2: ",
        "  Arm/Group Title: Docetaxel Plus Capecitabine",
        "  Arm/Group Description: docetaxel 75 mg/m2, intravenous, day 1 every 21 days plus capecitabine 1000 mg/m2, by mouth twice a day, days 1-14 every 21 days. Treatment continues until progression of disease, at which time crossover treatment begins.",
        "  Overall Number of Participants Analyzed: 236",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  8.88        (7.37 to 11.05)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 72/237 (30.38%)",
        "  Anaemia 2/237 (0.84%)",
        "  Disseminated intravascular coagulation 1/237 (0.42%)",
        "  Febrile neutropenia 9/237 (3.80%)",
        "  Leukocytosis 1/237 (0.42%)",
        "  Leukopenia 6/237 (2.53%)",
        "  Lymphopenia 1/237 (0.42%)",
        "  Neutropenia 25/237 (10.55%)",
        "  Thrombocytopenia 2/237 (0.84%)",
        "  Atrial fibrillation 0/237 (0.00%)",
        "  Cardiac failure congestive 2/237 (0.84%)",
        "Adverse Events 2:",
        "  Total: 55/226 (24.34%)",
        "  Anaemia 1/226 (0.44%)",
        "  Disseminated intravascular coagulation 0/226 (0.00%)",
        "  Febrile neutropenia 9/226 (3.98%)",
        "  Leukocytosis 0/226 (0.00%)",
        "  Leukopenia 2/226 (0.88%)",
        "  Lymphopenia 0/226 (0.00%)",
        "  Neutropenia 7/226 (3.10%)",
        "  Thrombocytopenia 0/226 (0.00%)",
        "  Atrial fibrillation 1/226 (0.44%)",
        "  Cardiac failure congestive 0/226 (0.00%)"
    ]
}